DURHAM, N.C., Nov. 17 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC:OXBT) (BULLETIN BOARD: OXBT) today announced that the company has begun shipping Dermacyte(TM) Oxygen Concentrate Gel to customers who have pre-ordered through the BuyDermacyte.com website. The shipments, which are going out today, cover orders received through early November. "This is a major milestone event for our company - actually shipping a product to customers and generating revenue as a result," said Chris Stern, company chairman and CEO. "Orders are continuing to come in and we will be shipping on a regular basis. We believe that our new cosmetic line has the potential to be a significant financial contributor and intend to move forward with our aggressive market and product plans and pursue our goal to cover our running costs with product sales." The gel is a first product of a broad and diverse Dermacyte product line in development. It uses a combination of patented and secret formulations to make the skin appear moist and more youthful. Dermacyte Oxygen Concentrate Gel can be purchased directly from the company via the secure ordering website at http://www.buydermacyte.com/. About Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at http://www.oxybiomed.com/. Caution Regarding Forward-Looking Statements This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. referring to expectations and plans for Dermacyte Oxygen Concentrate Gel that involve risks and uncertainties and reflect the company's judgment as of the date of this release. There can be no assurance that Dermacyte orders will grow or even continue or that Dermacyte sales will cover running costs or contribute any meaningful revenue to the company. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via http://www.oxybiomed.com/. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. DATASOURCE: Oxygen Biotherapeutics, Inc. CONTACT: Abe Wischnia of Abe Wischnia & Associates, +1-619-795-2345, for Oxygen Biotherapeutics, Inc. Web Site: http://www.oxybiomed.com/ http://www.buydermacyte.com/

Copyright